YOUR SEARCH FOR Text 17 RESULTS
11 of Total
Incyte Reports 2025 Second Quarter Financial Results and Provides Updates on Key Clinical Programs |
… its potentially first-in-class CDK2 inhibitor (INCB123667), in ovarian cancer in 2025 and is also evaluating INCB123667 in combination with other treatments. …
12 of Total
Incyte Reports 2024 Second Quarter Financial Results and Provides Updates on Key Clinical Programs |
… cancer: Phase 2 (POD1UM-101, POD1UM-204) INCB123667 (CDK2i) Solid tumors with … axatilimab, mCALR, JAK2V617Fi, retifanlimab, INCB123667, KRASG12Di and our TGF-β program; …
13 of Total
Incyte Reports 2022 Third Quarter Financial Results and Provides Updates on Key Clinical Programs |
… INCB99318 (PD-L1), INCB106385 (A2A/A2B), INCB123667 (CDK2) Monoclonal antibodies 1 …
14 of Total
Incyte Reports 2022 Fourth Quarter and Year-end Financial Results, Provides 2023 Financial Guidance
… INCB81776 (AXL/MER), INCB106385 (A2A/A2B), INCB123667 (CDK2) Monoclonal antibodies …
15 of Total
Incyte Reports 2023 Second Quarter Financial Results and Provides Updates on Key Clinical Programs |
… Modality Candidates Small molecules INCB123667 (CDK2) Monoclonal antibodies …
16 of Total
Incyte Reports 2023 Third Quarter Financial Results and Provides Updates on Key Clinical Programs |
View all news Incyte Reports 2023 Third Quarter Financial Results and Provides Updates on Key Clinical Programs October 31, 2023 at 7:00 AM EDT PDF
17 of Total
Incyte Reports Third Quarter 2025 Financial Results and Provides Business Updates | Incyte
… development efforts. A Phase 2 trial evaluating INCB123667 (CDK2i) in patients with …